Metraipolis › archive › dc_9319f15be992

Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach — Europe PMC PMID:41810428

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41810428
DOI
10.1016/j.jhepr.2026.101742
License (as archived)
solo-consultazione
Archived
2026-11-06T11:56:29.488Z
SHA-256 of the archived text
f2c272fd795705c45c7908c53656e2fed1f5810e4f5b25ccac65a5aebb6d3678
Stable URL of this page
https://metraipolis.com/documento/dc_9319f15be992

How to cite

Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach — Europe PMC PMID:41810428 — Europe PMC (en), https://europepmc.org/article/MED/41810428 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9319f15be992 (Metraipolis archive dc_9319f15be992, sha256 f2c272fd795705c45c7908c53656e2fed1f5810e4f5b25ccac65a5aebb6d3678)
BibTeX
@misc{dc9319f15be992,
  title = {Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach — Europe PMC PMID:41810428},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41810428},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9319f15be992; sha256 f2c272fd795705c45c7908c53656e2fed1f5810e4f5b25ccac65a5aebb6d3678},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41810428. Agents can read the archived copy with the MCP tool read_document.